30 results about "Ocular tension" patented technology

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w / v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

The invention relates to a Schlemm canal expandable stent and combination bodies of the Schlemm canal expandable stent. The expandable stent is a hollow shell with a cylindrical surface. The cylindrical surface is composed of round continuous curved rings formed in the manner that an alloy wire is bent and then bent back. The surface of the alloy wire is coated with a coating with the thickness ranging from 10 microns to 50 microns. The coating comprises an adhesive bottom layer and a drug layer. By means of the Schlemm canal expandable stent, damage of the stent wall to the wall of a Schlemm canal can be reduced, the occurrence rate of restenosis and proliferation of a Schlemm canal cavity can be lowered, and excellent flexibility is achieved. The Schlemm canal expandable stent can enable drugs to be effectively and permanently released at a narrow diseased region, reduce serious damage of the stent wall to the wall of the Schlemm canal and ensure accurate local dosing to a target diseased point, thereby being capable of more effectively lowering the occurrence rate of restenosis of the Schlemm canal and achieving the purposes of promoting discharging of aqueous humo, reducing intraocular pressure and treating glaucoma.

Because vision loss in most forms of glaucoma is related to elevated IOP, most glaucoma treatment protocols are concerned with lowering IOP by increasing aqueous humor outflow. The invention utilizes electromagnetic radiation to create retraction in the iris tissue, thereby (a) reducing convexity and enlarging the drainage angle and thus the area of the anterior chamber, (b) reducing contact between the zonule fibers and the iris pigment epithelium, (c) applying greater tension to both the TM and uveoscleral outflow pathways, thereby enlarging those pathways and increasing outflow.

Provided are manufacturing of a glaucoma internal drainage replacement bionic support and an application method thereof. Through proper placing and fixation, aqueous fluid smoothly flows into a Schlemm tube through a pipe orifice supported by the bionic support, through filling of aqueous fluid, the collapse Schlemm tube is expanded again, and the aqueous fluid is drained to a collecting tube and an aqueous vein, to achieve an objective of reducing intraocular tension and treating glaucoma. A new glaucoma internal drainage replacement bionic support implantation greatly reduces operation cost and reduces operation cost for a patient while maintaining advantages of a nonpenetrating glaucoma surgery. Combined with a trabeculectomy, adaptation diseases of the glaucoma internal drainage replacement bionic support are expanded, and new thinking and suggestion are provided for treatment of glaucoma.

The invention relates to a Schlemm tube expansion bracket and a combined body of the Schlemm tube expansion bracket. The expansion bracket is a hollow cylindrical shell; the cylindrical surface is formed by a continuous round curve loop bent and folded from an alloy wire; the surface of the alloy wire is coated with a coating of 10-50 microns, and the coating comprises an adhesive bottom layer and a drug layer. The tube expansion bracket disclosed by the invention can reduce the damage to the wall of a Schlemm tube, reduces restenosis and multiplication occurrence rate of a cavity of the Schlemm tube, and has good soft performance. The Schlemm tube expansion bracket disclosed by the invention can effectively and lastingly release the drug on a narrow lesion site, and guarantees local precise drug delivery of a target lesion point while reducing a serious damage on the wall of the Schlemm tube caused by the bracket wall, and therefore, the restenosis occurrence rate of the Schlemm tube can be effectively reduced, thereby achieving the purposes of promoting aqueous humour discharge, reducing intraocular tension and treating glaucoma.

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.

Disclosed is a gene sensitive to a normal-tension glaucoma disease. Also disclosed is a method for utilizing the gene. Comprehensive analysis / comparison was made on single nucleotide polymorphisms on the entire genome in many normal-tension glaucoma patients and many normal persons, and it is found that there is a difference in polymorphism sites found in ELOVL5-containing regions on human chromosome-6 and the like among the patients and the normal persons, wherein the polymorphism sites are represented by the international single nucleotide polymorphism numbers rs222450, rs9474394, rs2816344, rs2816341, rs2518579, rs2518578, rs9367511, rs6915699, rs6930045, rs9370188, rs9382180, rs9382181, rs4486010, rs2816379, rs6939730, rs2817088, rs2817090, rs2816372, rs2562895, rs2816364, rs2562893, rs2817101, rs2816362, rs2816356, rs10948744, rs12183976, rs2562898, rs735860, rs715441, rs2057024, rs1429146, rs9463895, rs2235723, rs1346603, rs9474476, rs2294867, rs9349660, rs974323, rs6909592, rs9367520, rs9395854, rs209485, rs9395856, rs7747926, rs7738788, rs209500, rs9357760, rs9370196, rs209512, rs209517, rs9370201, rs9367529, rs12209741, rs7744451, rs6904083, rs6904376, rs9367532, rs2067833, rs9382212, rs2139077, rs2397146, rs7742367, rs9474576, rs622447, rs3736729, rs13212365 and rs761141. It becomes possible to diagnose normal-tension glaucoma based on the difference in those polymorphism sites.

The present invention provides a composition for ocular topical administration for treating ocular hypertension and glaucoma, comprising latanoprost as an active ingredient, and (a) a polyol and / or sugar alcohol, (b) a nonionic surface active agent, and (c) an edetic acid compound. The composition of the present invention comprises lower amount of preservatives such as benzalkonium chloride comparative to the conventional product and therefore, can reduce incidence of the adverse side effects caused by the preservatives. In addition, the composition of the present invention can be stored stably at room temperatures for a long term.

The invention discloses an aqueous humor drainage device and a manufacturing method thereof. The aqueous humor drainage device is in a tubular structure and comprises a tube body portion and two clamping ring portions, the wall of the tube body portion is in a porous structure, and the outer peripheral wall of the tube body portion between the two clamping ring portions is provided with a clampinggroove. When the aqueous humor drainage device is implanted, the aqueous humor drainage device can be implanted into an intraocular suprachoroidal space through an injection implanter and is clampedon the scleral spur through the clamping groove; after implantation, the hollow tube cavity of the tube body portion and the porous structure of the tube wall jointly play a role in aqueous humor drainage, and a perpetual passage of the anterior chamber and the suprachoroidal space can be formed; after the aqueous humor drainage device is implanted into the suprachoroidal space, aqueous humor canflows into the ciliary body and the suprachoroidal space through the hollow tube cavity and the porous structure of the tube wall to play a role in intraocular tension reduction and glaucoma treatment. A manufacturing process of the aqueous humor drainage device is simple, and one-time sintering forming, large-batch production and high production efficiency can be realized.

The invention provides a medicinal composition with the function of protecting optic nerve, which is a preparation prepared by the following raw materials in part by weight: 40 to 400 parts of medlar and 45 to 480 parts of erigeron breviscapus. The medicament is used for treating optic neuropathy caused by liver and kidney deficiency and optic collateral stasis. The research shows that the medicinal composition has the function of protecting optic nerve. The invention is the optic nerve protection medicament for treating retinal diseases mainly comprising normal tension glaucoma, retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa and Leber's disease.

The present invention relates to a method of treating an ophthalmological disease mediated by ocular hypertension or an intestinal disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a tautomer, a pharmaceutically acceptable salt, a prodrug or a solvate thereof.

It is intended to provide a method of relieving or avoiding a steroid-induced increase in ocular tension which is caused by the administration of a steroid compound. Namely, a steroid-induced increase in ocular tension can be relieved or avoided by enclosing a steroid compound in fine particles.

The invention relates to the field of medicinal chemistry and pharmacotherapeutics, in particular to a nitric oxide (NO) donor type ripasudil derivative as well as a preparation method and an application thereof. The derivative reserves relatively strong ROCK inhibitory activity, inhibits myosin light chain phosphorylation of trabecular meshwork cells, and relaxes a trabecular meshwork aqueous humor efflux pathway; the released NO can relax a trabecular meshy aqueous humor drainage pathway and inhibit aqueous humor generation, and the NO and the aqueous humor cooperate to reduce intraocular pressure and protect retinal ganglion cells of a high intraocular pressure model mouse. The invention relates to NO donor type rivasdil derivatives or pharmaceutically acceptable salts thereof, preparation methods of the NO donor type rivasdil derivatives and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compounds and medical application of the compounds,in particular to application of the compounds in preparation of medicines for preventing and / or treating ophthalmic diseases such as glaucoma and ocular hypertension.

The invention relates to the use of substituted cyclopentanes or cyclopentanones as ocular hypotensives. New Compounds are also provided.

The purpose of the present invention is to discover a pharmaceutical preparation which is for treating or preventing glaucoma or intraocular hypertension and exhibits effects on a patient in which theefficacy of a therapeutic agent for glaucoma or intraocular hypertension is insufficient. It is found that omidenepag, an ester thereof, or a salt thereof is proven to exhibit an excellent intraocular tension depressive action on a patient in which the efficacies of other therapeutic agents for glaucoma or intraocular hypertension are insufficient. Therefore, omidenepag, an ester thereof, or a salt thereof according to the present invention is useful as a pharmaceutical preparation capable of treating or preventing glaucoma or intraocular hypertension even on a patient in which the efficaciesof other therapeutic agents for glaucoma or intraocular hypertension are insufficient.

The invention relates to the technical field of stents used in ophthalmology departments and in particular relates to a phase-change cooling stent as well as a preparation method and a phase-change cooling combined stent thereof. The invention provides the phase-change cooling stent which comprises a spiral shell and a core material, wherein the spiral shell is of a hollow structure; the core material is filled into the spiral shell; the core material is a phase-change cooling material; the spiral shell is a medical polymer material; and the outer diameter of the phase-change cooling stent isadaptive to the inner diameter of a Schlemm's canal. According to the phase-change cooling stent, the phase-change cooling material is adopted as a core layer component, the phase-change cooling material automatically absorbs heat from or releases heat to the environment through phase or structure change of self, so that the purpose of regulating and controlling ambient temperatures is achieved; by virtue of the properties that partial temperatures of trabecular meshwork tissue can be reduced by the phase-change cooling material, and wrong folding or accumulation of proteins of trabecular meshwork cells is reverted or blocked through a low temperature environment, the state that out-flowing of an aqueous fluid is blocked can be alleviated, and through repeated actions of the phase-change process, an effect that intraocular pressure is continuously reduced through one time of interference can be achieved.

The invention discloses gel and a preparation method thereof, and belongs to the field of tissue material engineering. The gel is prepared from active substances comprising the following three components, wherein the first component is PEG (Polyethylene Glycol) modified by N-hydroxysuccinimide-glutaric acid ester; the second component is polylysine; and the third component is a thickening agent. The active substance does not include amino-modified polyethylene glycol and amino-modified polyoxyethylene derivatives. The swelling property of the gel disclosed by the invention can keep low swelling and low shrinkage in a range of up to 180 days, which is a key factor for ophthalmology use because if the swelling rate of the vitreous body substitute is high, intraocular pressure can be increased to cause glaucoma, and if the swelling rate of the fundus gel is high, the retina can be pulled to cause retinal detachment.

A post-positioned stress-type glaucoma drainage valve, relating to a method and device for ophthalmic surgery, in particular to a post-positioned glaucoma drainage implantation device for controlling intraocular pressure, comprising a hollow drainage tube and a valve for controlling the opening of the drainage tube. The valve cover is closed, and the outlet end of the drainage pipe is provided with an openable cover, which is composed of a drainage plate and a cover cover. The outlet end of the drainage pipe is embedded in the drainage plate, and the inlet end of the drainage pipe is perpendicular to the drainage plate. The lower surface of the lower surface protrudes downward from the lower surface of the drainage plate, and the drainage pipeline can be entered by a 23G or 25G puncture knife at the pars plana of the ciliary body; a spring pressure device is provided on the inner side of the cover and the position corresponding to the valve cover; When the cover is closed, the spring pressure device exerts pressure on the valve cover, and the spring pressure device is used to control the intraocular pressure within the normal and safe target intraocular pressure range. The inner diameter of the drainage tube is large, the length is short, and it is not easy to block , which is conducive to ensuring the safety and effectiveness of the drainage valve and realizing long-term control of intraocular pressure.

The invention provides applications of NO and / or NO donor in preparation of a drug for preventing and / or assisting to treat open-angle glaucoma and the drug, and relates to the technical field of medicines. The administration characteristic of the drug is intranasal administration; the NO has the efficacy of adjusting blood circulation, promoting the recovery of trabecular functions and adjustingimmunity to promote inflammation to subside, so that intraocular pressure can be prevented or reduced; and in addition, the NO can also take part in adjusting systemic arteriovenous pressure and cerebrospinal fluid pressure, so that pressure across sieve plates can be affected so as to affect the development and outcome of the open-angle glaucoma.

The invention provides compositions and methods for further reducing IOP in a subject who has already achieved maximal IOP reduction using known IOP lowering agents. The activity of an ocular hypotensive treatment regimen may be increased by adding an S1P antagonist to prevent S1P mediated reversal as a result of decreased aqueous humor outflow.

The invention discloses a schlemm canal dilatation stent. The dilatation stent comprises a catheter, a stent body and a guide head, wherein the radian of the catheter is the same as that of a schlemmcanal; the outer side of the catheter is sleeved with the stent body, and the curvature radius of the stent body is the same as that of the catheter; the guide head is arranged at a first end of the catheter; the diameter of the catheter is smaller than the inner diameter of the schlemm canal; and the catheter is made of an elastic material, and the stent body is made of a plastic material. The dilatation effect of the schlemm canal dilatation stent on the schlemm canal is flexible and controllable; and a new aqueous humor outflow channel is formed in a trabecular meshwork, so that the aqueoushumor outflow resistance is reduced, damage to the trabecular meshwork is reduced, bleeding is reduced, related complications are reduced, and intraocular pressure is stably reduced.

2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5′-monophosphate, or salts thereof; and drugs containing the same as an active ingredient. The compounds have excellent effects of lowering ocular tension, promoting blood flow in retina, and protecting optic nerve failure and are highly soluble in water. Owing to these characteristics, the compounds are useful as drugs such as remedies for glaucoma and ocular hypertension.

RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.